NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

Minesh Mehta

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancer
Volume	126
State	Published - Jun 15 2020

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

@article{e70b0ca7afa242b09035a5cf66a53aaa,

title = "NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma",

author = "Minesh Mehta",

note = "Cancer (2020) 126(12):2821-2828",

year = "2020",

month = jun,

day = "15",

language = "American English",

volume = "126",

journal = "Cancer",

}

TY - JOUR

T1 - NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

AU - Mehta, Minesh

N1 - Cancer (2020) 126(12):2821-2828

PY - 2020/6/15

Y1 - 2020/6/15

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3476

M3 - Article

VL - 126

JO - Cancer

JF - Cancer

ER -

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

Access to Document

Other files and links

Cite this